Evidence Hub

A case report of stage IV inoperable gastric cancer demonstrating a cCR treated with S-1/Paclitaxe (l PTX) therapy

Owada Y, Okada K, Ebisui C, Makino S, Kato R, Nishigaki T, Murakami M, Yanagisawa T et al.

Gan to kagaku ryoho. Cancer & chemotherapy, 2011

Abstract

We report a case of Stage IV inoperable gastric cancer demonstrating a cCR treated with S-1/PTX. The patient was a 65-year-old female with advanced gastric cancer. CT scan suggested an invasion of tumor into a pancreatic body, jejunum and transverse colon. Staging laparoscopy showed it to be positive with peritoneal washing cytology and peritoneal dissemination. The surgical findings were T4a (SE) N2M1H0P1CY1, Stage IV. Chemotherapy was conducted with a combination of S-1/CDDP. After 2 courses of this regimen, the endoscopy findings did not show an improvement, so we decided to change the chemotherapy to S-1/PTX as second-line treatment. After 2 courses of this regimen, the endoscopy findings revealed a reduction of the primary tumor. After 19 courses, histopathological examination of biopsy specimen showed Group 1. Second-line chemotherapy was continued for 28 courses. The patient has had no recurrence without chemotherapy and been alive for 91 months after diagnosis.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free